SCHEMBL5161504

SCHEMBL5161504

CN(C)C(=O)CC(=O)c1ccc2ccccc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
GAA P10253 2/20 0.55
LMNA P02545 1/20 0.55
MAPT P10636 1/20 0.55
MGAM O43451 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
CNR2 P34972 3/20 0.51
HPGD P15428 2/20 0.50
KDM4C Q9H3R0 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
KDM4E B2RXH2 3/20 0.49
OPRM1 P35372 1/20 0.49
OPRK1 P41145 1/20 0.49
TMEM97 Q5BJF2 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
NPC1 O15118 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
RAB9A P51151 3/20 0.49
NFKB1 P19838 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160847 0.85 ALDH1A1 (0.53) ALDH1A1GAALMNAMAPTMGAM
SCHEMBL9664008 0.82 ALDH1A1 (0.60) ALDH1A1GAAMAPTMGAMHDAC8
SCHEMBL5160087 0.79 ALDH1A1 (0.58) ALDH1A1GAAMAPTMGAMHDAC8
SCHEMBL5158144 0.79 ALDH1A1 (0.57) ALDH1A1GAAMAPTMGAMHDAC8
SCHEMBL1460111 0.79 KMT2A (0.57) ALDH1A1GAAMAPTMGAMHDAC8
SCHEMBL5163053 0.79 ALDH1A1 (0.70) ALDH1A1GAAMAPTMGAMHDAC8
SCHEMBL30417045 0.78 MGAM (0.61) ALDH1A1GAALMNAMAPTMGAM
SCHEMBL8237398 0.78 MGAM (0.61) ALDH1A1GAALMNAMAPTMGAM
SCHEMBL1839801 0.78 LMNA (0.64) ALDH1A1GAALMNAMAPTMGAM
SCHEMBL8906407 0.78 ALDH1A1 (0.55) ALDH1A1GAAMAPTMGAMHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885GAA 1272/4885LMNA 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.